Collaboration will leverage Envisagenics'
SpliceCore® AI platform for accelerated discovery and development
of oncology therapeutic candidates
NEW
YORK, Nov. 29, 2022 /PRNewswire/ --
Envisagenics, an Artificial Intelligence ("AI")-driven
biotechnology company that delivers therapies for RNA splicing
diseases, today announced a research collaboration agreement with
Bristol Myers Squibb (NYSE:
BMY). The multi-year collaboration will leverage Envisagenics'
SpliceCore® AI platform to identify alternative splicing derived
targets for therapeutic development to expand Bristol Myers
Squibb's vast oncology pipeline. Envisagenics will receive an
upfront payment and milestone payments based on development,
regulatory, and commercial achievements.
Envisagenics, an AI-driven biotech that
focuses on RNA splicing diseases, announced a research
collaboration with BMS.
SpliceCore, a cloud-based, AI-powered platform, can identify
disease-specific splicing-derived targets by using RNA-sequencing
data. Envisagenics will integrate data from thousands of
patients to identify mRNAs encoding for tumor-specific cell surface
antigens, thereby fostering the discovery of novel targets to
enable development of therapeutics.
"It is exciting to see how quickly significant scientific
breakthroughs in the biopharma industry can be achieved with the
assistance of AI," said Maria Luisa
Pineda, Ph.D., Envisagenics' CEO and Co-founder. "Our
SpliceCore platform, coupled with Bristol Myers Squibb's expertise,
has the potential to accelerate target identification, transform
modern drug development, and improve patient outcomes."
The SpliceCore platform applies an ensemble of proprietary
algorithms to RNA-sequencing data, creating a sequence search space
of approximately 7 million splicing events, thus maximizing the
odds of drug target discovery. SpliceCore prioritizes drug targets
based on their disease-specificity, biological roles, and
druggability through a variety of drug modalities. Thanks to its
scalable and cost-effective cloud architecture, the platform can
process massive amounts of RNA-seq data efficiently and at high
speed. SpliceCore helps to identify drug targets quickly and, in
turn, predicts drug-responding alternative splicing events for
therapeutic development.
Martin Akerman, Ph.D.,
Envisagenics' CTO and Co-founder, added, "novel therapeutic targets
are urgently needed for patients, and Envisagenics is thrilled to
be collaborating with BMS as part of our quest for innovation."
About Envisagenics
Envisagenics is an Artificial Intelligence-driven biotechnology
company that focuses on the discovery of novel RNA splicing
variants that cause cancer and other genetic diseases. Its
principal technology is the SpliceCore® discovery platform. The
platform re-envisions the human genome with a validated
exon-centric approach, combined with machine learning algorithms
and high-performance computing. It is up to 250 times more likely
to discover novel targets than gene-centric discovery tools. Using
innovative technology and RNA analysis expertise, Envisagenics
accelerates the development of highly specific therapeutics that
modulate RNA splicing events that drive pathogenesis of oncology,
neurodegenerative, and metabolic disorders.
Envisagenics partners with biopharmaceutical companies and
academic institutions to advance their drug discovery capabilities.
Envisagenics also has its own internally developed RNA therapeutic
programs. Envisagenics is a spin-out of Cold Spring Harbor
Laboratory and a proud woman- and minority-led recipient of several
grants from the National Institute of General Medical Sciences and
the National Cancer Institute.
For more information, please visit www.envisagenics.com.
Follow us on – Twitter, LinkedIn, YouTube.
Envisagenics Media Contact
Bradley Harris
press@envisagenics.com
Tel: (929) 777-2001
View original
content:https://www.prnewswire.com/news-releases/envisagenics-announces-research-collaboration-with-bristol-myers-squibb-301687320.html
SOURCE Envisagenics